{"nctId":"NCT00472797","briefTitle":"Rebif New Formulation (RNF) Quality of Life (QOL) Study","startDateStruct":{"date":"2007-04"},"conditions":["Relapsing Multiple Sclerosis"],"count":232,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rebif New Formulation Non Titrated"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rebif New Formulation Titrated"]}],"interventions":[{"name":"Rebif New Formulation Non Titrated","otherNames":[]},{"name":"Rebif New Formulation Titrated","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject with a relapsing form of MS; diagnosis of MS is in accordance with the McDonald criteria\n2. Subject currently taking Rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment\n3. Subject currently using Rebiject II and 29 gauge needle\n4. Subject is between 18 and 60 years old inclusive\n5. Subject is able to read and understand English\n6. Subject is willing to follow study procedures\n7. Subject has given written informed consent and signed HIPAA\n8. Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) Being post-menopausal or surgically sterile, or ii) Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (Confirmation required within 30 days prior to start of the study)\n\nExclusion Criteria:\n\n1. Use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. Receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's Rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable\n2. Subject receiving MS therapy in addition (i.e., combination therapy) to Rebif® within 3 months prior to study enrollment or at any time during study protocol.\n3. Subjects who have previously been on Rebif New Formulation (RNF).\n4. Subject with progressive forms of Multiple Sclerosis (MS).\n5. Subject with history of any chronic pain syndrome.\n6. Subject has any other disease apart from MS that could better explain the subjects signs and symptoms.\n7. Subject has complete transverse myelitis or bilateral optic neuritis.\n8. Subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1.\n9. Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1 (prior to enrollment).\n10. Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase \\> 2.5 times the upper limit of the normal values.\n11. Subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.\n12. Subject suffers from other current autoimmune disease.\n13. Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol\n14. Subject is pregnant or attempting to conceive\n15. Visual or physical impairment that precludes completion of diaries and questionnaires.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)","description":"The MSTCQ Global Side Effect domain assesses the degree of satisfaction on global side effect questions 9, 10 \\& 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied). Percent change calculated as 100% \\* (score at week 12 - score at baseline) / score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)","description":"The MSTCQ Global Side Effect domain assesses the subjects degree of satisfaction on global side effect questions 9, 10 \\& 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"1.7"},{"groupId":"OG001","value":"13.4","spread":"1.8"},{"groupId":"OG002","value":"13.4","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"1.6"},{"groupId":"OG001","value":"13.8","spread":"1.6"},{"groupId":"OG002","value":"13.9","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"16.5"},{"groupId":"OG001","value":"4.5","spread":"18.8"},{"groupId":"OG002","value":"5.0","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)","description":"The MSTCQ in all domains assesses quality of life. The score for all domains other than the Global Side Effect ranges from 17 (most favorable) to 85 (least favorable). Change calculated as (score at week 12 - score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"4.0"},{"groupId":"OG001","value":"-2.9","spread":"4.1"},{"groupId":"OG002","value":"-3.1","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"6.4"},{"groupId":"OG001","value":"-2.3","spread":"5.7"},{"groupId":"OG002","value":"-2.8","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"3.6"},{"groupId":"OG001","value":"-0.8","spread":"3.6"},{"groupId":"OG002","value":"-0.8","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.2"},{"groupId":"OG001","value":"-1.3","spread":"2.9"},{"groupId":"OG002","value":"-1.6","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"8.8"},{"groupId":"OG001","value":"-5.3","spread":"7.6"},{"groupId":"OG002","value":"-6.0","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12","description":"The SF-MPQ assesses Tolerability of Pain with 15 questions to evaluate the type and severity of pain experienced 60 minutes after an injection of study drug. Scores range from 0 (no pain) to 45 (severe pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"3.4"},{"groupId":"OG001","value":"1.1","spread":"3.9"},{"groupId":"OG002","value":"0.9","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Tolerability in Pain Using Visual Analog Scale (VAS)","description":"The SF-MPQ included a visual analog scale, ranging from 0 to 100 mm, on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm). A rating of \\<5 mm was considered pain-free.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability - Redness at Injection Site","description":"Change in Baseline to Week 12 Last Observation Carried Forward(LOCF)- A blinded assessment of injection site redness was conducted by a health care professional (1-72 hours) after the most recent injection measuring redness at its widest diameter in mm. Diameter of Redness, lower is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"27.7"},{"groupId":"OG001","value":"-3.1","spread":"28.2"},{"groupId":"OG002","value":"-2.7","spread":"27.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"SF-36 Physical and Mental Component Scores","description":"Change from Baseline to each visit for Physical and Mental Component scores for SF-36. Score is norm-based with a mean of 50 and a standard deviation of 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":"9.4"},{"groupId":"OG001","value":"43.6","spread":"9.3"},{"groupId":"OG002","value":"43.5","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"5.7"},{"groupId":"OG001","value":"2.0","spread":"4.3"},{"groupId":"OG002","value":"1.9","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"7.7"},{"groupId":"OG001","value":"1.5","spread":"6.0"},{"groupId":"OG002","value":"0.6","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"6.5"},{"groupId":"OG001","value":"1.7","spread":"6.6"},{"groupId":"OG002","value":"1.9","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"6.5"},{"groupId":"OG001","value":"2.0","spread":"6.4"},{"groupId":"OG002","value":"1.5","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"6.4"},{"groupId":"OG001","value":"1.4","spread":"6.4"},{"groupId":"OG002","value":"0.9","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":"10.9"},{"groupId":"OG001","value":"46.1","spread":"10.9"},{"groupId":"OG002","value":"46.1","spread":"10.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"8.7"},{"groupId":"OG001","value":"1.3","spread":"9.1"},{"groupId":"OG002","value":"1.9","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"10.6"},{"groupId":"OG001","value":"-0.8","spread":"10.0"},{"groupId":"OG002","value":"0.5","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"10.7"},{"groupId":"OG001","value":"-1.2","spread":"8.9"},{"groupId":"OG002","value":"-0.4","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"11.2"},{"groupId":"OG001","value":"0.1","spread":"10.4"},{"groupId":"OG002","value":"0.7","spread":"10.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"11.2"},{"groupId":"OG001","value":"0.1","spread":"9.7"},{"groupId":"OG002","value":"0.0","spread":"10.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":118},"commonTop":["Headache","Pain","Influenza-like Illness","Nasopharyngitis","Urinary tract infection"]}}}